Develops drug candidates for cancer and inflammatory and autoimmune diseases, and licenses programs to pharmaceutical partners.
10-K for FY2025, filed Feb 25, 2026
Partners pay Arcus for program licenses, research and development, and clinical materials through upfront fees and milestones; service revenue is earned as work is performed, and royalties can be tied to licensed-product sales.
10-K for FY2025, filed Feb 25, 2026We are a clinical-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of…View ↗
We currently do not have product sales and our revenues are derived from research, collaboration and license arrangements with strategic…View ↗
In arrangements involving more than one performance obligation, each performance obligation is evaluated to determine whether it qualifies…View ↗
For arrangements that include sales-based royalties, including milestone payments based on sales thresholds, and for which the license is…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$247M
10-K for FY2025, filed Feb 25, 2026
$247M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License and development services
Licensed
10-K for FY2025, filed Feb 25, 2026 |
89% |
License and development services, FY2025
$221M Sources
|
Licensed |
|
Other Collaboration Revenue
|
11%
FY2022: 34%
|
Other Collaboration Revenue, FY2025
$26M Sources
|
Arcus works through license and collaboration agreements with pharmaceutical partners: Gilead holds licenses to cancer programs, while Taiho has regional rights to several programs. Arcus also co-develops selected programs with Gilead.
10-K for FY2025, filed Feb 25, 2026In 2020, we and Gilead entered into the Gilead Collaboration Agreement, as amended, under which Gilead obtained an exclusive license to…View ↗
In 2017, we entered into the Taiho Agreement pursuant to which Taiho obtained an exclusive option to in-license the development and…View ↗
For each program that Gilead has exercised its option, both companies will co-develop and equally share global development costs, subject…View ↗
10-K for FY2025, filed Feb 25, 2026
Revenues from Gilead accounted for 97%, 94% and 96% of Total revenues for the years ended December 31, 2025, 2024 and 2023, respectively.View ↗
No. It lost $353M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$128MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Apr 20, 2026
On April 20, 2026, the Company announced that the period for Gilead’s option rights under the Option, License and Collaboration Agreement…View ↗
Shrinking. Revenue fell 36% in 4 years, from $383M in FY2021 to $247M in FY2025, about 10% a year.
A broader research focus
The older report centered its oncology portfolio on domvanalimab and zimberelimab combinations. The latest report foregrounds casdatifan studies in kidney cancer and describes inflammation and autoimmune discovery programs using small molecules.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and…View ↗
Our first Phase 3 clinical trial, PEAK-1, is evaluating casdatifan and cabozantinib in ccRCC patients that have received prior…View ↗
Inflammation ProgramsView ↗
We have active discovery efforts focused on the creation of development candidates aimed at regulating excessive immune activity in the…View ↗
Competes with AstraZeneca, BeiGene, Bristol-Myer Squibb, Merck, Novartis, Pfizer, Regeneron, Sanofi, Roche/Genentech, Celldex Therapeutics, Abbvie, Amgen, NiKang Therapeutics, Arrowhead Pharmaceuticals, I-MAB Biopharma, Incyte, Innate Pharma, Innovent Biologics, Antengene, and ORIC Pharmaceuticals
10-K for FY2025, filed Feb 25, 2026We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop treatments for cancer and…View ↗
Loading...